UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for heart failure in the United Kingdom. Explore treatment pathways including medications, devices, and emerging therapies.
Heart failure affects over 1 million people in the UK, with ~200,000 new diagnoses per year. It occurs when the heart cannot pump blood effectively. There are two main types: HFrEF (reduced ejection fraction, ~50%) and HFpEF (preserved ejection fraction). Outcomes have improved dramatically with modern medications, but heart failure remains a significant cause of hospital admissions and mortality.
The "four pillars" of HFrEF treatment: (1) ACE inhibitor/ARB/ARNI (sacubitril-valsartan), (2) Beta-blocker (bisoprolol, carvedilol), (3) Mineralocorticoid receptor antagonist (spironolactone, eplerenone), (4) SGLT2 inhibitor (dapagliflozin, empagliflozin). All four should be started promptly. For HFpEF, SGLT2 inhibitors are the first class to show clear benefit. Device therapy (ICD, CRT) for eligible patients.
Active UK heart failure trials include: gene therapy (injecting genes to improve heart function), stem cell therapy, novel cardiac myosin activators, new SGLT2/ARNI combinations, remote monitoring devices, and telemedicine-guided management. The BHF (British Heart Foundation) funds major UK heart failure research programmes.
Free AI-powered matching - no signup required
Search cardiac failure Trials →